Antares Pharma Posts Narrower Loss In Q4 - Quick Facts

(RTTNews) - Antares Pharma, Inc. (ATRS) reported a fourth-quarter net loss of $3.7 million compared to a loss of $4.5 million in the comparable period in 2016. Net loss per share was $0.02 compared to a loss of $0.03. On average, five analysts polled by Thomson Reuters expected the company to report a loss per share of $0.03 for the quarter. Analysts' estimates typically exclude special items.

Fourth-quarter total revenue was $14.0 million compared to $14.2 million, prior year. Product sales were $11.0 million, compared to $9.7 million, and Development revenue was $2.2 million, compared to $3.8 million for the comparable period in 2016. Analysts expected revenue of $15.65 million for the quarter.

Robert Apple, CEO, said: "While we diligently work on moving our XYOSTED testosterone regulatory application forward, we continue to support our partner Teva, on their three pending drug-device abbreviated new drug applications. We remain focused on growing both our commercial business and our pipeline in 2018 with the potential filing of an investigational new drug application in the second half of this year."